INMB Stock Summary and Trading Ideas (Inmune Bio | NASDAQ:INMB)

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Inmune Bio trades on the NASDAQ stock market under the symbol INMB.

As of September 25, 2026, INMB stock price declined to $1.97 with 43,939 million shares trading.

INMB has a beta of 2.59, meaning it tends to be more sensitive to market movements. INMB has a correlation of 0.24 to the broad based SPY ETF.

INMB has a market cap of $54.67 million. This is considered a Micro Cap stock.

In the last 3 years, INMB traded as high as $14.74 and as low as $1.09.

The top ETF exchange traded funds that INMB belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAS.

INMB has underperformed the market in the last year with a price return of +1.0% while the SPY ETF gained +17.4%. However, in the short term, INMB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +45.9% vs +5.0% return in SPY. But in the last 2 weeks, INMB shares have been beat by the market, returning -14.7% compared to an SPY return of +1.6%.

INMB support price is $1.90 and resistance is $2.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INMB shares will trade within this expected range on the day.